NextGen Biomed Ltd. — Investor Presentation 2026

Jan 14, 2026

{0}------------------------------------------------

Breath-Based Diagnostics

Scentech Medical Shareholder Update (MAYA Disclosure)

Company Overview, Development Progress, and Strategic Transactions

This presentation contains forward-looking statements

{1}------------------------------------------------

Forward-looking Information

This presentation is intended to provide a general overview for your convenience. It cannot take the place of the tests published for public release, which include the full company information, prior to making any decision on investing in the Company shares. This presentation contains forward-looking information as defined in the Securities Law, 1968. This information contains, inter alia, forecasts, goals and estimates relating to future events and/or issues that might not materialize and/or which are not under the Company's exclusive control.

Forward-looking information is not a proven fact and is by its very nature subject to significant risks of non-materialization. The said information is neither certain nor can it be accurately forecast, and its materialization or lack of materialization may be influenced, inter alia, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors impacting the Company that cannot be forecast and which are not under the Company's control.

In view of the above, the readers of this presentation are reminded that the actual results and achievements of the Company in the future are likely to substantially differ from those presented in the forward- looking information included in this presentation, and that the Company's assumptions regarding completion of the initiative are not certain, and possibly might not be completed in the current format or at all, in light of the fact that completion of the initiative is subject to completion of the conditions and milestones that have yet to reach fruition and/or be completed. Accordingly, completion of the venture is not certain and depends on all the above taking place and this might not materialize or might do so only in part or differently than what is stated above, and thus is considered forward-looking informationas defined inthe Securities Law.

Moreover, the forecasts and estimates of the forward-looking information are based on information and data available to the Company at the time of publishing the presentation, and the Company does not undertake to update and/or change each forecast and/or estimate in order to reflect events and/or circumstances that might occur after the presentation's date of publication.

{2}------------------------------------------------

Vision

To become a global leader in early disease detection and biological security, transforming diagnostics through VOC*-based technologies.

{3}------------------------------------------------

Mission

To save lives by developing non-invasive, real-time detection systems for pathogens and cancers using advanced VOC biomarker analysis.

{4}------------------------------------------------

Company Overview

Scentech is a pre-commercial diagnostics company developing a unified platform for early disease detection and infection monitoring based on volatile organic compound (VOC) analysis.

Non-invasive VOC-based diagnostics Focused on oncology and infectious disease applications

Platform architecture shared across multiple indications

Focused on advancing VOC-based diagnostics toward clinical validation and commercialization

{5}------------------------------------------------

THE CLINICAL PROBLEM

The Clinical Problem

• Many diagnostic workflows are reactive, delivering actionable information late
• Pancreatic cancer is frequently diagnosed at advanced stages
• Hospital infection decisions are often made before pathogen identification is available

{6}------------------------------------------------

VOC-Based Biomarkers as an Early Biochemical Indicator

VOCs reflect metabolic and microbial activity associated with disease

Represent a biochemical layer distinct from genetic, proteomic, or imaging approaches

Can be captured using non-invasive or low-burden sampling methods

Under active clinical and laboratory investigation

{7}------------------------------------------------

Platform Architecture

• Standardized VOC acquisition
• Regulated analytical instrumentation
• Centralized cloud analytics and ML
• Governed data pipelines

The architecture shown provides a high-level overview applicable to multiple sample types and applications.

{8}------------------------------------------------

Platform Workflow

(Conceptual)

analysis

{9}------------------------------------------------

The VOX Platform Overview

Non-Invasive Breath-Based VOC Diagnostic Platform

Breath Sample Collection

Standardized collection of exhaled breath samples for VOC analysis

Analytical Instrumentation

Analytical processing using regulated laboratory-grade instrumentation

Cloud Analytics

Centralized cloud-based analytics and machine-learning interpretation

Structured Output

Governed data pipelines and algorithm version control

VOX is designed as a breath-based platform intended to support early biochemical signal detection for oncology applications.

* Illustrative schematic. VOX is under development. No products have received regulatory approval.

{10}------------------------------------------------

Primary Applications of the VOX Platform

Application	Who Cares / Who Pays
Infectious Disease	Hospitals, Public Health Agencies,
Detection & Monitoring	Screening Programs, Ministries of Health
Early Cancer Detection	Cancer Centers, Hospitals, Screening
(Pancreatic, Colon, Additional Cancers)	Programs, Private Healthcare Providers
Biosecurity & Mass-Screening	Governments, Homeland Security, Airports,
(Airports, Borders, Public Venues)	Airlines, Public Venues
Point-of-Care & Rapid Clinical	ERs, Clinics, Urgent Care, Rural Health
Decision Support	Centers, LMIC Health Systems
Hospital-Associated Infection	Hospitals, Infection Control Units,
Detection (HAIs)	Health Systems
High-Throughput Clinical	National Health Systems, Public
Screening Programs	Health Programs, NGOs

{11}------------------------------------------------

UNDER DEVELOPMENT

Products Under Development

Product	Clinical Focus	Core Value
VOX (Under Development)	Non-invasive breath-baseddiagnostic with initial focus onpancreatic cancer. Intended as anupstream triage tool.	A non-invasive way to help identifycancer risk earlier within existingcare pathways.
VocTracer (UnderDevelopment)	VOC-based infection and AMRdetection intended to supportearlier infection assessment	Early biochemical insight to helpassess infections alongside standardmicrobiology methods.

{12}------------------------------------------------

Early Cancer Detection

{13}------------------------------------------------

VOCTRACER

Infection & Antimicrobial Resistance Detection

VOC -based infection and AMR detection under development

Intended to support earlier infection assessment

Complements existing microbiology workflows

Designed to complement culture -based and molecular microbiology methods.

{14}------------------------------------------------

Revenue Model

{15}------------------------------------------------

Development Progress to Date

Completion of COVID-19 VOC research and testing activities.

Ongoing research and development of biomarkers.

Peer-reviewed publications related to VOC biomarker research.

Ongoing research collaboration with Shamir Medical Center.

Joint biomarker research and publications with LSRI and IIBR (previously disclosed).

Fully operational analytical laboratory supporting VOC R&D.

Biomarker research conducted across multiple disease signatures.

{16}------------------------------------------------

Roadmap

VOX system optimization & engineering improvements

Ongoing internal VOC biomarker research programs.

Clinical study planning and initiation activities

Pancreatic cancer clinical study enrollment activities

Analytical model and software development Additional indication preparation (Colon and Gastric cancer)

HAIs/AMR related clinical program development and regulatory planning activities

Ongoing clinical data collection and analysis activities

Regulatory pathway evaluation and preparation Analytical model development and continued biomarker research

Post-clearance preparation activities

Developing a pipeline of disease indications and regulatory pathways

Current Phase

Next Phase Future Phase

{17}------------------------------------------------

Regulatory Status

• Pre-commercial; no regulatory approvals to date
• Clinical and analytical validation ongoing
• Regulatory pathways under evaluation
• Commercialization contingent on regulatory clearance

{18}------------------------------------------------

Strategic Transaction with RELI

• Scentech entered into a transaction with RELI (details previously disclosed)
• Transaction supports continued development of the platform
• Aligns capital structure with current development stage
• Does not constitute regulatory approval or commercial launch

Refer to published disclosures for full transaction details.

{19}------------------------------------------------

Near -Term Focus Areas Advance clinical validation programs

• Prepare for regulatory engagement
• Continue platform refinement
• Maintain capital discipline